Abstract
Aim: To evaluate the clinical outcomes and severity of disease in COVID-19 patients presenting with and without comorbidities. 
 Study Design: Cross-sectional study.
 Place and Duration: ICUs, wards of Jinnah Postgraduate Medical Center Karachi from March, to June 2021.
 Methodology: The enrolled patients diagnosed with COVID-19 ie according to the provisional directions given by WHO, were assessed for clinical outcomes. Comorbidities were determined based on patients self-report on admission. 
 Results: Total 200 COVID patients were enrolled in the study, out of them 179 were with comorbidities like type 2 Diabetes mellitus, hypertension, cardiac disorders and asthma, while 21 COVID patients were with no co morbidity. In present study (n=200), 55.5% were belonging to the age group more than fifty five years old, there were 50.5% males and 29.5% patients came in the month of June 2021. There were 84% hypertensive, 54% were diabetic, 10% were Ischemic Heart Disease and 5% were Asthmatic patients. Clinical outcomes, i.e., pneumothorax, pulmonary embolism, Myocardial Infarction, septic shock, heart failure, Disseminated Intravascular Coagulation was compared regarding associated co-morbidities at the time of admission, p-value was <0.01 and x2=20.15 .
 Conclusion: COVID patients with comorbidities are more at risk of developing worst clinical outcomes.
Highlights
Coronavirus disease 2019 (COVID-19) is a diverse infectious health condition concerning miscellaneous causal pathophysiological processes include endothelial damage, hyper inflammation, thrombotic microangiopathies as well as end-organ injuries [1]
Co-morbidities found significantly highly prevailing in severe COVID-19 cases, i.e., raised blood pressure but yet no understandable alliance exist between COVID-19 mortality and comorbidity [4]
The enrolled patients diagnosed with COVID-19 according to the provisional directions given by WHO and the clinical outcomes measured
Summary
Coronavirus disease 2019 (COVID-19) is a diverse infectious health condition concerning miscellaneous causal pathophysiological processes include endothelial damage, hyper inflammation, thrombotic microangiopathies as well as end-organ injuries [1]. It has been revealed as being caused by severe acute respiratory syndrome coronavirus 2 abbreviated as SARS-CoV-2 and it be initially recognized in December of 2019 in Wuhan city of China, and it had been spread world –wide and created HAVOC globally and culminated in increased mortality in about two hundred and twenty countries. Co-morbidities found significantly highly prevailing in severe COVID-19 cases, i.e., raised blood pressure but yet no understandable alliance exist between COVID-19 mortality and comorbidity [4]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
